February 2022 Editor's pick Jolien Blokken

In this section of the BJMO, we provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here was made by PROF. DR. HANS PRENEN (Oncologist, University Hospital Antwerp, and member of the BJMO editorial board), based on the added value of the studies in daily clinical practice. In addition to the key highlights of the articles, an expert opinion of Prof. Prenen on each of these topics is included.

The KEYNOTE-811 trial evaluating dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Treatment options for patients with HER2-positive advanced gastric cancer are limited and the prognosis for these patients is poor. Initial data from the phase III Keynote-811 study now support pembrolizumab plus trastuzumab and chemotherapy as a possible new first-line treatment option for HER2-positive, metastatic gastric or gastroesophageal junction cancer… Read more

Combination of relatlimab and nivolumab improves PFS in advanced melanoma

RELATIVITY-047 is a phase III trial that evaluated the dual inhibition of LAG-3 and PD-1 using a new combination of relatlimab, a human IgG4 LAG-3–blocking antibody, and nivolumab as compared to the current standard therapy of nivolumab monotherapy, in patients with melanoma. Primary results demonstrate that the trial met its primary endpoint of improved progression-free survival without any unexpected toxicities… Read more

Modest activity of sotorasib in KRASG12C-mutated colorectal cancer

In the phase II CodeBreaK100 trial, sotorasib monotherapy showed modest activity and notable median progression-free survival and overall survival for patients with heavily pre-treated, refractory KRASG12C-mutated colorectal cancer who have limited effective treatment options. Furthermore, targeted treatment with sotorasib was tolerable and displayed a manageable safety profile… Read more

Nivolumab plus low-dose ipilimumab as a first-line treatment for MSI-H/dMMR mCRC

In an updated analysis of the phase II CheckMate 142 trial with median follow-up of 20.9 months, nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)… Read more

Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival

Thus far, treatment for patients with recurrent ovarian cancer has been largely based on systemic therapy while the role of secondary cytoreductive surgery remained unclear. Results of the DESKTOP III trial now demonstrate that in carefully selected women with recurrent ovarian cancer, cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone… Read more